Search

Your search keyword '"Leary, Alexandra"' showing total 894 results

Search Constraints

Start Over You searched for: Author "Leary, Alexandra" Remove constraint Author: "Leary, Alexandra"
894 results on '"Leary, Alexandra"'

Search Results

1. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

2. The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research

3. Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer: Alexandra Leary

4. ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

7. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

8. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

9. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

13. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation

16. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

17. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

18. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

19. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).

21. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer

22. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts

23. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

25. Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.

26. Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial.

27. An evaluation of cell-free tumor DNA from 20 mL of peritoneal fluid for homologous recombination deficiency (HRD) testing in newly diagnosed ovarian cancer (OC).

28. Unveiling the unique identity of clear-cell endometrial cancer (CCEC): A comprehensive comparative analysis with ovarian counterpart and other endometrial subtypes.

30. Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.

32. Exploring the tumor microenvironment (TME) in patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) undergoing immune checkpoint inhibitor (ICI) therapy: Proteomic insights into immune resistance mechanisms.

34. Prediction of recurrence risk in endometrial cancer with multimodal deep learning

35. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era

38. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients

39. Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.

40. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

43. Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy

44. Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection

46. Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

47. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

48. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

50. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Catalog

Books, media, physical & digital resources